1 / 8

Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United Sta

Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United States, 2009 to 2011. Mitchell A. Yakrus, MS, MPH. Microbiologist Laboratory Branch 16 th Annual Conference The Union-North American Region February 25, 2012.

dewitt
Télécharger la présentation

Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United Sta

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United States, 2009 to 2011 Mitchell A. Yakrus, MS, MPH Microbiologist Laboratory Branch 16th Annual Conference The Union-North American Region February 25, 2012 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination

  2. Background • CDC’s DTBE Laboratory Branch provides a service for the molecular detection of drug resistance (MDDR) to rapidly identify multidrug-resistant isolates of Mycobacterium tuberculosis complex (MTBC) • DNA sequencing of 9 genetic loci associated with resistance to first and second-line drugs • Concurrently perform growth-based conventional drug susceptibility testing (DST) • Agar proportion for 12 first and second-line antituberculosis drugs • MGIT 960 for pyrazinamide • MTBC isolates must meet specific criteria before submission for MDDR

  3. MDDR Request/Approval MDDR Isolate Received Conventional DST Molecular Analysis Molecular Results (Interim Report) Molecular + Conventional DST Results (Final Report)

  4. Methods • Received 285 requests for MDDR testing from 43 public health laboratories from September 2009 to February 2011 • Analyzed agreement between molecular and conventional results for rifampin (RMP) and isoniazid (INH) • Examined submission criteria as indicated on request forms for possible association with resistance to RMP or INH • Isolate known to be multi-drug resistant (MDR) • Patient previously treated for tuberculosis (TB) • Patient from an area with a high rate of drug resistance (foreign born)

  5. Agreement Between Molecular and Conventional Testing

  6. Association of RMP or INH Resistance with Submission Criteria

  7. Summary • MDDR was highly concordant with drug resistance results from growth-based conventional testing • Detection of resistance to RMP or INH was not significantly associated with specific submission criteria with the exception of whether isolates were submitted as known MDR • Further analysis of the association of submission criteria with results is needed to optimize testing algorithms • Need to collect clinical outcome data for patients to measure impact of rapidly identifying drug resistance and discordant results

  8. Acknowledgements • Angela M. Starks , PhD, Team Lead, Laboratory Capacity • Beverly Metchock, Dr. P.H. , D(ABMM), Team Lead, Reference Team

More Related